Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been newly diagnosed with a mature B-cell non-Hodgkin lymphoma or classical Hodgkin lymphoma, confirmed by a tissue or cell sample test, and who fall into one of the specific categories below
- People with Burkitt lymphoma, Burkitt-like lymphoma with an 11q chromosomal change, diffuse large B-cell lymphoma, or high-grade B-cell lymphoma at an advanced stage — either stage III with elevated blood enzyme levels (LDH at least twice the upper limit of normal), or stage IV with a small amount of lymphoma in the bone marrow (5–24%) (Cohort Ia)
- People with any of the above lymphoma types that has spread to the brain or spinal fluid, or has heavily affected the bone marrow (25% or more lymphoma cells), or whose tumour did not shrink by at least 20% after an initial round of chemotherapy (Cohort Ib)
- People with classical Hodgkin lymphoma at intermediate risk — including certain stage I, II, or IIIA presentations, with or without a large tumour mass or nearby spread (Cohort IIa)
- People with classical Hodgkin lymphoma at high risk — including stage IIB with a large tumour mass, stage IIIA with a large tumour mass, stage IIIB, or stage IV (Cohort IIb)
- People whose heart, liver, kidneys, and other organs are functioning well enough to participate (confirm with trial site)
Who may not be able to join:
- People whose lymphoma is classified as primary mediastinal B-cell lymphoma
- People with T-cell/histiocyte-rich large B-cell lymphoma
- People with gray zone lymphoma
- People with follicular lymphoma
- People with nodular lymphocyte-predominant Hodgkin lymphoma
- People with lymphoma that developed after an organ or stem cell transplant (post-transplant lymphoproliferative disorder)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Mitchell Cairo, MD, New York Medical Center
Phone: 9145942150
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Grade 3 and 4 Adverse Events related to polatuzumab vedotin; Grade 3 and 4 Adverse events related to nivolumab
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.